Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith A Aberg

Showing results (81-90 of 211) with videos related to

Pageof 22
Sort By:
Antimicrobial Agents and Chemotherapy|February 28, 2023
Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 StudySean T H Liu, Mila Mirceta, Grace Lin, et al.
Journal of General Internal Medicine|March 10, 2022
Association of Vaccination with the Persistence of Post-COVID SymptomsJuan P Wisnivesky, Usha Govindarajulu, Emilia Bagiella, et al.
Clinical Pharmacology and Therapeutics|August 9, 2005
Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockersMarshall J Glesby, Judith A Aberg, Michelle A Kendall, et al.
AIDS Research and Human Retroviruses|February 23, 2012
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeksJudith A Aberg, Pablo Tebas, Edgar Turner Overton, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 28, 2005
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 StudyJohn G Gerber, Susan L Rosenkranz, Carl J Fichtenbaum, et al.
The Lancet. HIV|July 16, 2019
Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling studyLinwei Wang, Emanuel Krebs, Jeong E Min, et al.
The Journal of Infectious Diseases|July 1, 2020
Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency VirusHsi-En Ho, Michael J Peluso, Colton Margus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2009
Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of AmericaJudith A Aberg, Jonathan E Kaplan, Howard Libman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2013
Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot studyMeagan O'Brien, Emilie Montenont, Liang Hu, et al.
AIDS (London, England)|September 10, 2010
Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229Grace A McComsey, Ulrich A Walker, Chakra B Budhathoki, et al.
Pageof 22

Showing results (81-90 of 211) with videos related to

Sort By:
Pageof 22
Antimicrobial Agents and Chemotherapy|February 28, 2023
Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 StudySean T H Liu, Mila Mirceta, Grace Lin, et al.
Journal of General Internal Medicine|March 10, 2022
Association of Vaccination with the Persistence of Post-COVID SymptomsJuan P Wisnivesky, Usha Govindarajulu, Emilia Bagiella, et al.
Clinical Pharmacology and Therapeutics|August 9, 2005
Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockersMarshall J Glesby, Judith A Aberg, Michelle A Kendall, et al.
AIDS Research and Human Retroviruses|February 23, 2012
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeksJudith A Aberg, Pablo Tebas, Edgar Turner Overton, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 28, 2005
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 StudyJohn G Gerber, Susan L Rosenkranz, Carl J Fichtenbaum, et al.
The Lancet. HIV|July 16, 2019
Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling studyLinwei Wang, Emanuel Krebs, Jeong E Min, et al.
The Journal of Infectious Diseases|July 1, 2020
Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency VirusHsi-En Ho, Michael J Peluso, Colton Margus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2009
Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of AmericaJudith A Aberg, Jonathan E Kaplan, Howard Libman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2013
Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot studyMeagan O'Brien, Emilie Montenont, Liang Hu, et al.
AIDS (London, England)|September 10, 2010
Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229Grace A McComsey, Ulrich A Walker, Chakra B Budhathoki, et al.
Pageof 22